Menu
Recruiting NCT06182293

Periodontal Microbiota in Systemic Sclerosis

No phase Interventional Scleroderma Systemic

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota.
Who it may be relevant to
Registry conditions: Scleroderma Systemic. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Impact of Systemic Sclerosis on the Periodontal Microbiota: a Pilot Study

Overview

Systemic sclerosis (SSc) is a rare and complex autoimmune disease. Although its etiology remains unknown, various environmental factors, including certain microorganisms, can represent potential triggers of SSc in individuals with a permissive genetic background. Patients show a wide spectrum of clinical features including periodontitis, which is an inflammatory disease of the tooth-supporting tissues resulting from dysbiosis of the periodontal microbiota guided by inflammophilic bacteria. The microbiota plays a fundamental role in the induction, training, and function of the host immune system. Numerous studies have highlighted the impact of an altered microbiota, i.e. dysbiosis, on the pathogenesis of immune-mediated diseases. Indeed, commensals are important to maintain immune homeostasis and changes in the microbial composition can be responsible for a loss of tolerance. SSc has been shown to be associated with gut dysbiosis and a depletion of commensals. However, although the oral cavity is one of the two largest microbial habitats, only one study (only focusing on Lactobacillus species) has investigated the oral microbiota in SSc. As periodontal dysbiosis is known to induce low-grade systemic inflammation and represents a risk factor for the development of various autoimmune diseases, the relationship between periodontal microbiota composition and SSc merits further exploration. The aim of this pilot study is to characterize the taxonomic composition and metabolic pathways of the periodontal microbiota in SSc patients and age and sex-matched controls.

Interventions

  • Other Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota
    Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.

Primary outcome measures

  • Alpha diversity of the periodontal microbiota using Chao-1 index [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

Common inclusion criteria

  • Men or women over 18 (adults)
  • Affiliation to a social health insurance plan
  • Subject able to understand the aims and risks of the research and to give signed informed consent form prior to the inclusion in the study
  • More than 12 teeth suitable for evaluation

Inclusion criteria for systemic sclerosis patients

  • Systemic sclerosis patient with a diagnosis based on the American College of Rheumatology/European League Against Rheumatism criteria (LeRoy et al., 1988 ; van den Hoogen et al., 2013)
  • Diagnosis made during the 2 years preceding study inclusion (early form of the disease)

Inclusion criteria for controls

\- Patient attending the Oral Medicine and Surgery Department from the University Hospital of Strasbourg for a routine dental consultation

Exclusion criteria

  • \- Subject under court protection
  • Subject under guardianship or curatorship
  • Pregnancy or breastfeeding
  • Impossibility to provide accurate information (emergency situation, comprehension difficulties…)
  • Subject currently involved in another clinical trial or in an exclusion period following participation in another clinical trial
  • Smoking (≥ 10 cigarettes per day)
  • Other associated systemic auto-immune disease (Sjögren syndrome with positive serum anti-SSA and/or anti-SSB auto-antibodies, systemic lupus erythematosus…)
  • Progressive chronic illness other than systemic sclerosis
  • Acute infection at inclusion
  • Progressive cancer or cancer diagnosed within 2 years prior to the study
  • Ongoing antibiotic and/or antifungal treatment or within 3 months prior to inclusion
  • Probiotics and/or prebiotics intake within 3 months prior to inclusion
  • Oral antiseptics within the week before inclusion (chlorhexidin mouthwashes…)
  • Risk of infective endocarditis
  • Corticosteroids ≥10 mg/day and/or proton pump inhibitors within 3 months prior to inclusion
  • Previous hematopoietic stem cell transplantation
  • Another cause of skin sclerosis (radiotherapy of the orofacial area…)
  • Periodontal specialized treatments, root and/or periodontal surgical treatment and/or subgingival instrumentation within the year before inclusion

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Basic science

Study locations

France · 1 center
  • Clinique Dentaire — Strasbourg

Identifiers

NCT: NCT06182293 · 9149

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗